Patton named CEO of OneOncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jeff Patton was named chief executive officer of OneOncology. Patton has been Acting CEO and president of Physician Services since February.

Jeff Patton

OneOncology includes five practices throughout the U.S., represents over 400 providers, and cares for approximately 250,000 patients annually at 160 sites of care. OneOncology partner practices deliver integrated oncology care services including screening and diagnosis, clinical trials, therapies, and survivorship or end-of-life care. A main responsibility of OneOncology is to help its partner practices expand services in cancer care.

“We formed OneOncology in 2018 with the idea that with physician leadership, common technology platforms, and access to capital, practices could have both the necessary scale and local decision-making authority needed to not only survive but thrive in today’s marketplace,” Patton said in a statement. “Today, as practices grapple with COVID-19 and plan for caring for patients post peak, the ideas that brought us together are exactly what will propel our future growth.”

Patton will continue as the executive chairman of the board at Tennessee Oncology.

Table of Contents

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login